SCHEMBL6570157

SCHEMBL6570157

O=C(Cc1c[nH]c2ccccc12)NN=Cc1ccccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 1.00
ALDH1A1 P00352 4/20 1.00
KDM4E B2RXH2 4/20 1.00
GAA P10253 3/20 1.00
GLA P06280 1/20 1.00
NPSR1 Q6W5P4 2/20 0.69
LMNA P02545 2/20 0.68
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
POLB P06746 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.61
FAAH O00519 1/20 0.58
RAB9A P51151 1/20 0.57
PTGS2 P35354 1/20 0.56
HTT P42858 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
HPGD P15428 2/20 0.55
TAAR1 Q96RJ0 1/20 0.53
CTRC Q99895 1/20 0.52
DUSP3 P51452 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6747952 1.00 MAPT (1.00) MAPTALDH1A1KDM4EGAAGLA
SCHEMBL12508920 0.86 MAPT (0.76) MAPTALDH1A1KDM4EGAAGLA
SCHEMBL13381119 0.85 MAPT (0.74) MAPTALDH1A1KDM4EGAAGLA
SCHEMBL13381141 0.81 ALDH1A1 (0.79) MAPTALDH1A1KDM4EGAAGLA
SCHEMBL13381133 0.81 ALDH1A1 (1.00) MAPTALDH1A1KDM4EGAAGLA
SCHEMBL13381145 0.79 MAPT (0.65) MAPTALDH1A1KDM4EGAAGLA
SCHEMBL13381103 0.78 MAPT (1.00) MAPTALDH1A1KDM4EGAAGLA
SCHEMBL13381082 0.78 MEN1 (0.70) MAPTALDH1A1KDM4EGAAGLA
SCHEMBL394413 0.77 FAAH (0.72) MAPTALDH1A1KDM4EGAAGLA
SCHEMBL23706957 0.77 ALDH1A1 (0.65) MAPTALDH1A1KDM4EGAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP claimed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO MAPT 3140/4885ALDH1A1 956/4885KDM4E 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.